FTSE 100 movers: M&S climbs on update; Glencore slips on downgrade
7th Apr 2016 13:04
(ShareCast News) - London's FTSE 100 index was down 0.1% to 6,154.99 at 1410 BST, although retailer M&S bucked the trend. Payments processor Worldpay was under pressure after private equity groups Advent International and Bain Capital sold a 12.5% stake in the company. Glencore fell after JP Morgan
Read moreLondon pre-open: Slightly higher start expected
7th Apr 2016 07:08
(ShareCast News) - Stocks were expected to start the morning higher, tracking strong gains on Wall Street in the wake of the latest set of Federal Reserve meeting minutes which revealed deep divisions among the US central bank's rate-setters. The FTSE 100 was being called to start the day up by eigh
Read moreShire sees Baxalta deal proceeding despite US tax rules
7th Apr 2016 07:05
(ShareCast News) - Pharmaceuticals firm Shire said it expected its $32bn (£22.6bn) merger with Baxalta to go ahead despite new US tax rules stopping the $160bn deal between Pfizer and Allergan. In a statement, Shire said it expected the Baxalta transaction would proceed as originally announced on Ja
Read moreWednesday broker round-up
6th Apr 2016 14:37
(ShareCast News) - Electrocomponents: Credit Suisse upgrades to neutral with a target price of 250p. Telecom Plus: Berenberg Bank downgrades to hold, 250p target. Informa: Berenberg Bank maintains hold with a target price of 725p. ITV: Credit Suisse reiterates outperform with a target price of 310
Read moreLondon-listed pharmas rally as Pfizer-Allergan deal collapses
6th Apr 2016 10:20
(ShareCast News) - Shares in pharmaceuticals companies Shire, AstraZeneca and GlaxoSmithKline rallied on Wednesday as investors bet that the termination of Pfizer's agreement to buy Allergan might make the London-listed companies bid targets. US drug maker Pfizer said on Wednesday that its $160bn ag
Read moreTuesday broker round-up
5th Apr 2016 15:09
(ShareCast News) - Royal Mail: Investec reiterates buy with a target price of 580p. Gooch Housego: Investec reiterates buy, 1020p target and Finncap keeps at hold. Glencore: Exane BNP Paribas maintains outperform with a target price of 165p. Babcock: JP Morgan reiterates overweight with a targe
Read moreShire wins US patent trial for ulcerative colitis drug Lialda
29th Mar 2016 12:43
(ShareCast News) - The United States District Court for Southern Florida has upheld Shire's patent for ulcerative colitis drug Lialda in the US until 2020. The decision follows litigation by Shire against Allergan's Watson unit in connection with its abbreviated new drug application for a generic ve
Read moreBroker tips: Tullow Oil, Sainsbury's, Shire
21st Mar 2016 12:34
(ShareCast News) - Jefferies downgraded Tullow Oil to 'underperform' from 'hold' with an unchanged price target of 166p. The bank said it was increasingly concerned over operational issues at the Jubilee field, which is a fundamental stock risk overriding opportunity from oil shows in a new Kenya ba
Read moreShire rallies as Exane says it's just too cheap
21st Mar 2016 11:59
(ShareCast News) - Pharmaceuticals group Shire was the standout gainer on the FTSE 100 on Monday as Exane BNP Paribas said the stock looked too cheap. The bank said it was selling its position in Swiss pharma company Roche and switching into Shire. "Shire, on a forward P/E of just 12 for top line g
Read moreFTSE 100 movers: Budget takes wealth managers, house builders higher
16th Mar 2016 14:54
(ShareCast News) - The FTSE 100 was higher in afternoon trading on Wednesday, as investors digested the Chancellor's lunchtime Budget statement. Wealth manager St James's Place led the risers, after Chancellor of the Exchequer George Osborne set out measures in the Budget to boost home ownership and
Read moreDirector dealing: Shire board shell out
15th Feb 2016 15:13
(ShareCast News) - With Shire shares almost £20 short of last year's all-time high, the drug developer's chairwoman, chief executive and a clutch of senior directors have splashed some cash to show what they think of the valuation. Seven board members put their money where their mouths were, having
Read moreShire sets out bullish guidance for 2016 after beating quarterly forecasts
11th Feb 2016 12:04
(ShareCast News) - Shire beat fourth quarter sales forecasts and issued much stronger guidance for 2016, targeting double digit top-line growth and a 7%-10% increase in earnings before including the effect of its takeover of Baxalta. Fourth quarter revenues rose 9% to $1.72bn, up 13% at constant exc
Read moreBroker tips: Shire, Dunelm, Glencore
10th Feb 2016 13:38
(ShareCast News) - RBC Capital Markets upgraded Shire to 'outperform' from 'sector perform', keeping the $240 price target ahead of the company's fourth quarter results on Thursday. RBC said that following the recent pullback, the share price reflects attractive value and future competitive threats
Read moreShire's deputy chairman David Kappler to step down
10th Feb 2016 12:36
(ShareCast News) - Specialty biopharmaceutical company Shire said David Kappler will step down as deputy chairman and senior independent director. Meanwhile, non-executive director William Burns will be appointed senior independent director, with both changes taking effect after the annual general m
Read moreRBC upgrades Shire to 'outperform' ahead of results
10th Feb 2016 12:22
(ShareCast News) - RBC Capital Markets upgraded Shire to 'outperform' from 'sector perform', keeping the $240 price target ahead of the company's fourth quarter results on Thursday. RBC said that following the recent pullback, the share price reflects attractive value and future competitive threats
Read more